Evaluating the antifibrotic potency of galunisertib in a human ex vivo model of liver fibrosis

BACKGROUND AND PURPOSE: Liver fibrosis is a major cause of liver‐related mortality and, so far, no effective antifibrotic drug is available. Galunisertib, a TGF‐β receptor type I kinase inhibitor, is a potential candidate for the treatment of liver fibrosis. Here, we evaluated the potency of galunis...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Br J Pharmacol
Auteurs principaux: Luangmonkong, Theerut, Suriguga, Su, Bigaeva, Emilia, Boersema, Miriam, Oosterhuis, Dorenda, de Jong, Koert P, Schuppan, Detlef, Mutsaers, Henricus A M, Olinga, Peter
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2017
Sujets:
Research Papers
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5573419/
https://ncbi.nlm.nih.gov/pubmed/28691737
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13945
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires